



## 91% capacity increase in major-stake hospital beds by FY28 drives long term performance; margins under pressure by upcoming two-hospital acquisition

Dallah is maintaining its momentum into H1-24, where it recorded a bottom line of SAR 231.1mn (up 56.5% Y/Y) and a top line reaching SAR 1,549.2mn (up 11.7%). Its recent performance has been attributed to a mix of improvements- starting with a top line supported by patient volume increases and minor price hikes, as well as margin expansions, operational capacity increases, and also increased income from associates which have already recorded a SAR 20.6mn for the half as compared to a loss of SAR 1.9mn in all of FY23. Going forward, Dallah seeks to finalize a two-hospital acquisition (AlAhsa at 205 beds, and AlSalam at 495 beds, both in the Eastern Region) via a share swap funded by a 3.99% capital increase. While AlSalam is a loss making hospital, as it was recently established, and AlAhsa's estimated revenue generation per bed at less than Dallah's, we expect Dallah to be able to immediately recognize synergies with the two hospitals via its economies of scale on cost controls, improving quality and sourcing medical talent, and potentially negotiating towards corporate contract clients. Furthermore, Dallah is expected to load up nearly SAR 764.0mn in Ayyan's total debt- though we expect Dallah's scale and more favorable credit rating to potentially open opportunities to refinance the debt at better terms. Along with an expansion in the up-and-coming district of AlArid expected in FY28, we estimate an FY23-28E revenue and net income CAGR of 12.7% and 20.4%, respectively; also supported by improvement in its associate companies. We revise our TP up to **SAR 172.0 per share**, at a "Neutral" recommendation.

**Increase in patient volume, operational capacity, performance of associate hospitals, and slight price hikes enhancing margins categorized healthy H1-24 results:** Dallah's H1-24 results reached a bottom line of SAR 231.1mn (up 56.5% Y/Y), while also recording a top line for the half reaching SAR 1,549.2mn (up 11.7% Y/Y). The double digit revenue growth came as a result of patients increasing by 1% Y/Y, and likely due to the 50 bed operational addition at Kingdom Hospital taking place towards the end of the period; in addition to favorable case mixes also supporting the period's revenues, price increases on insurance clients across mature and new facilities to match inflation (and higher for newly operated facilities) were also in effect. As a result of the cases mixes and price adjustments, GP margins for H1-24 reached 38.2%, with Q2-24's margins reaching its highest levels since 2018. Furthermore, contributions from its associate hospitals reached SAR 20.6mn in H1-24 as compared to an SAR 8mn loss Y/Y. Notably, Mohammed Al-Faqih hospital (currently 350 beds, and a 31.21% stake) recorded losses for Dallah at SAR 23.0mn in FY23, but decreased its loss contribution to just SAR 1.0mn throughout H1-24. Also, while increasing its stake in Jeddah's International Medical Center during FY23 (now at a 27.18% stake, currently hosting 300 beds), the associate hospital contributed SAR 15.1mn to the bottom line in H1-24 as compared to SAR 6.1mn throughout all of FY23. Dallah's H1-24 bottom line then reaches its highest net income for a first-half to date.

**Upcoming major transaction to acquire AlSalam Hospital and AlAhsa Hospital circumvents development risks and increases beds capacity by c. 63% over FY23 levels:** Dallah seeks to finalize its agreement by end of year to acquire 97.4% of AlAhsa Hospital, and 100% of Al Salaam Hospital from Ayyan Investment Co. via a share swap funded by a 3.99% capital increase, raising Dallah's number of shares to 101.57mn. Both hospitals are in the Eastern Region. AlAhsa hospital established in 1999 in Hofouf, has an estimated building capacity to host 205 beds and is a class B hospital in terms of insurance classifications. Al Salaam hospital, established in 2022 in AlKhobar, has a building capacity of 495 beds and is a class A/VIP hospital. The net equity value for the 100% and 97.41% acquisitions was reached at a total of SAR 660mn; with an acquired net book value of 218.3mn for AlAhsa, and a SAR -131.14mn for AlSalam. We estimate Dallah to load up nearly SAR 764.0mn of the acquirees' debt, though we expect that Dallah's financial profile, scale, and credit rating to be able to mitigate the acquirees' finance cost (estimated at an annualized c. 8% as of H1-24) should Dallah decide to refinance. Furthermore, at an estimated current EV for the deal at SAR 1.4bn (excluding lease liabilities), implies a cost of SAR 2.0mn per bed, below the average starting range of nearly SAR 2.5mn per-bed for a greenfield premium hospital project.

**Potentials from AlSalam and AlAhsa acquisition expected to be realized by medium term after a 410bps pressure on margins by FY25E over H1-24 levels:** We estimate both hospitals to generate a lesser total revenue to utilized beds than Dallah's. We do, however, expect Dallah to be able to enhance its acquirees' revenue generation via more specialized services, patient attraction, and possibly contract clients as a part of its initiatives post acquisition. However, with AlAhsa being a class B hospital, we expect more headroom for revenue enhancement from the newly established AlSalam hospital. We estimate a four year FY25-30E revenue CAGR from both hospitals reaching 17.0% on the back improved utilization rates and revenue enhancement post acquisition. AlSalam is currently a loss making hospital, as it is a new hospital; and while ramp ups towards break even could take up to three years for a new hospital, we expect the hospital to reach its breakeven point during FY26E. Competition in that region, however, is a risk on its ramp up time. The hospitals would be able to benefit by Dallah's brand equity, economies of scale on its costs, quality of doctors and sourcing talent, gaining accreditations, as well as its relationship with insurance clients and the ability to negotiate corporate client contracts. We expect the Ayyan acquisitions to pressure Dallah's recently heightened GP margins, to reach 34.1% in FY25 (down c. 410bps from H1-24 levels), as the hospitals ramp up. We forecast, however, for GP margins to recover to 37.0% by FY27E before facing some pressures from the FY28E AlArid expansion. At Dallah's scale and existing operational network, we expect immediate synergies to take place for the OPEX required to run the AlAhsa and AlSalam hospitals; pressuring operating margins by only 180bps, from FY23 levels, during their first full year, before gradually improving after. Going forward, we forecast a five year FY23-28E revenue and net income CAGR of 12.7% and 20.4%, respectively- mainly driven by the consolidation and ramping up of the upcoming acquirees.

Recommendation	Neutral
Target Price (SAR)	172.0
Upside / (Downside)*	7.0%

Source: Tadawul \*prices as of 17<sup>th</sup> of Sept 2024

### Key Financials

in SAR mn, (unless specified)	FY22	FY23	FY24E	FY25E
Revenues	2,488	2,943	3,256	3,987
Growth %	18.2%	18.3%	10.6%	22.5%
Net Income	274.5	360.1	463.1	430.4
Growth %	6.1%	31.2%	28.6%	-7.1%
EPS	2.70	3.70	4.56	4.24
DPS	2.00	2.00	2.00	2.0

Source: Company reports, Aljazira Capital Research

### Key Ratios

	FY22	FY23	FY24E	FY25E
Gross Margin	36.0%	36.7%	37.9%	34.1%
OP Margin	17.0%	17.2%	18.4%	15.4%
Net Margin	11.0%	12.2%	14.2%	10.8%
EBITDA Margin	21.6%	21.5%	23.3%	20.6%
RoE	14.2%	13.9%	12.6%	10.2%
P/E (x)	54.8	46.4	35.3x	37.9x
P/B (x)	6.7	5.2	4.0x	3.8x
EV/EBITDA (x)	31.2	30.4	24.9x	23.1x
Dividend Yield	1.4%	1.2%	1.2%	1.2%

Source: Company reports, Aljazira Capital Research

### Key Market Data

Market Cap (SAR bn)	15.7
YTD%	-6.4%
52 weeks (High)/(Low)	194.0/131.4
Share Outstanding (mn)	101.6

Source: Company reports, Aljazira Capital Research \*Post Acquisition

### Price Performance



Source: Tadawul, Aljazira Capital Research

Equity Analyst

Ibrahim Elaiwat

+966 11 2256115

i.elaiwat@Aljaziracapital.com.sa






**Total expansions to extend capacity by c. 91% over the current, post the FY28E AlArid expansion, driving long term performance for the stock:** On the immediate term, Dallah is set to gradually extend its Namar inpatient capacity by 100 beds per the need. We expect that utilization at Namar is near 70% or above, potentially warranting rolling out some of the 100 by the end of the year, and stretching onto FY25E. Furthermore, post the Ayyan acquisitions taking place by end of FY24, Dallah is expected to open up a 250 bed hospital in the up-and-coming AlArid district in Riyadh by FY28E. Dallah Clinics are also expected to open two clinics by H2-24E which are currently under refurbishment. We expect the expansion campaign underway to extend Dallah's capacity from the current estimated 1,154 beds to 2,204 beds (91% increase) by FY28E. The bottom line is expected to be supported by Dallah's portfolio of associates, which have already recorded a net contribution of SAR 20.6mn, as compared to a loss of SAR 1.9mn for all of FY23. Its associate, and premium provider, IMC, is also undergoing an expansion in Jeddah to potentially expand Dallah's income from associates, though we await further details on the expansion.


**AJC view and valuation:** Dallah possesses various growth drivers found in its upcoming Ayyan acquisition, AlArid expansion, its performance of its invested associates, as well as a potential expansion under study for its AlNakheel land. While the acquisition will load up Dallah's balance sheet with an estimated SAR 762.3mn in debt (which Ayyan pays an estimated annualized EIR of c. 8% as for H1-24), we expect that Dallah's credit rating and scale is able to mitigate the interest paid on the acquired interest bearing debts should Dallah refinance them. Furthermore, while AlSalam is a loss making hospital, which we forecast that Dallah's initiatives and synergies with the hospital to expedite the ramp up at the hospital. Our estimates on all the developments ongoing at Dallah punctuate at a FY23-28E revenue and net income CAGR of 12.7% and 20.4%, respectively. We do however expect that that intensified competition in the region to be a potential downside risk to the expected ramp up of AlSalam. Further downsides are present from longer than expected delays in expansions, which have happened at Dallah previously. While upsides are found in the success of materializing the AlNakheel land into an expansion, or higher than expected patient volumes or price hikes, as well as a quicker than expected ramp up at AlSalam. We value the stock at 50% DCF (terminal growth rate = 2.5%) and 50% PE (42x over FY25E earnings, based on a three year forward CAGR of 21.0%) to upwardly revise our TP to **SAR 172.0 per share**, at a **"Neutral"** recommendation.

**Fig. 1: Ayyan acquisition, AlArid, and Namar expansions to extend expected capacity by 91% over current**



Source: Company Presentations, AlJazira Capital Research

**Fig. 2: Average positive deviation of 22.4mn (TTM) driven by revenue and margin performance as well as associate income**



Sources: Company Financials, AlJazira Capital Research, Argam

#### Valuation Summary:

DCF	FY24E	FY25E	FY26E	FY27E	FY28E	FY29E	FY30E
Operating Profit	598.2	613.2	808.6	951.9	1,061.8	1,174.8	1,287.4
Depreciation & Amortization	130.4	172.5	186.0	191.6	221.3	225.1	228.4
Working capital chg	-132.8	-56.4	-47.5	-36.4	-73.5	-31.6	-19.5
<b>CFO</b>	<b>595.8</b>	<b>729.4</b>	<b>947.1</b>	<b>1,107.1</b>	<b>1,209.6</b>	<b>1,368.2</b>	<b>1,496.4</b>
Capex	(1,267.3)	(462.4)	(481.8)	(326.9)	(252.4)	(258.3)	(255.6)
FCFF	-671.5	266.9	465.3	780.2	957.3	1,109.9	1,240.7
<b>Present value of FCFF</b>	<b>-657.6</b>	<b>244.2</b>	<b>396.7</b>	<b>620.4</b>	<b>709.0</b>	<b>760.6</b>	<b>785.9</b>
Sum of the PV							2,859.2
PV of terminal value							16,008.4
<b>Enterprise Value</b>							<b>18,867.5</b>
Cash							143.0
Debt							1,782.6
Non-Controlling Interest							280.0
FV							16,947.9
<b>Fair value per share*</b>							<b>SAR 166.9</b>

Source: Company reports, AlJazira Capital Research \*Over post-acquisition number of shares

#### Blended Valuation

	Fair value	Weights	Weighted average
DCF based value	166.9	50%	83.4
Relative Valuation - P/E (42x - FY25E)	178.0	50%	89.0
<b>Weighted average 12-month price target</b>			<b>172.0</b>
<b>Expected Capital Gain</b>			<b>7.0%</b>

Source: Company reports, AlJazira Capital Research



Fig 4. Key Financials

Amount in SAR mn, unless otherwise specified	FY22	FY23	FY24E	FY25E	FY26E	FY27E	FY28E
<b>Income statement</b>							
Revenues	2,488.0	2,942.9	3,255.8	3,987.3	4,399.3	4,760.3	5,369.2
Y/Y	18.2%	18.3%	10.6%	22.5%	10.3%	8.2%	12.8%
Cost	(1,592.9)	(1,864.2)	(2,021.2)	(2,628.0)	(2,818.0)	(2,999.1)	(3,425.9)
<b>Gross profit</b>	<b>895.1</b>	<b>1,078.7</b>	<b>1,234.5</b>	<b>1,359.3</b>	<b>1,581.3</b>	<b>1,761.3</b>	<b>1,943.3</b>
Selling & distribution expense	(45.0)	(59.8)	(66.9)	(77.2)	(88.8)	(97.0)	(111.2)
General & administration expense	(429.8)	(517.1)	(569.2)	(664.0)	(677.3)	(703.7)	(761.2)
Expected credit loss provision	(27.8)	(30.2)	(32.2)	(36.9)	(41.7)	(46.8)	(52.0)
<b>Operating profit</b>	<b>392.5</b>	<b>471.6</b>	<b>566.3</b>	<b>581.3</b>	<b>773.4</b>	<b>913.8</b>	<b>1,018.8</b>
Y/Y	19.7%	20.2%	20.1%	2.7%	33.0%	18.2%	11.5%
Other income	30.0	34.7	31.9	31.9	35.2	38.1	43.0
Financial charges	(70.5)	(104.1)	(114.0)	(157.4)	(137.1)	(126.3)	(106.2)
Other adjustments	(22.8)	(1.9)	35.9	36.6	39.5	41.2	45.7
<b>Income before zakat</b>	<b>329.1</b>	<b>400.3</b>	<b>520.1</b>	<b>492.5</b>	<b>710.9</b>	<b>866.7</b>	<b>1,001.3</b>
Zakat	(33.7)	(14.9)	(21.7)	(24.6)	(35.5)	(37.8)	(50.1)
Non-controlling interest	(21.0)	(25.3)	(35.3)	(37.5)	(38.1)	(38.5)	(39.0)
<b>Net income</b>	<b>274.5</b>	<b>360.1</b>	<b>463.1</b>	<b>430.4</b>	<b>637.3</b>	<b>790.4</b>	<b>912.2</b>
Y/Y	6.1%	31.2%	28.6%	-7.1%	48.1%	24.0%	15.4%
<b>EPS</b>	<b>2.70</b>	<b>3.70</b>	<b>4.56</b>	<b>4.24</b>	<b>6.27</b>	<b>7.78</b>	<b>8.98</b>
<b>DPS</b>	<b>2.00</b>	<b>2.00</b>	<b>2.00</b>	<b>2.00</b>	<b>3.25</b>	<b>4.00</b>	<b>5.00</b>
<b>Balance sheet</b>							
<b>Assets</b>							
Cash & equivalent	238	235	72	204	281	151	223
Other current assets	1,066	1,110	1,291	1,492	1,599	1,686	1,871
Property plant & equipment	2,847	3,040	4,103	4,367	4,633	4,736	4,730
Other non-current assets	769	1,858	2,479	2,488	2,495	2,500	2,504
<b>Total assets</b>	<b>4,920</b>	<b>6,243</b>	<b>7,945</b>	<b>8,551</b>	<b>9,008</b>	<b>9,073</b>	<b>9,328</b>
<b>Liabilities &amp; owners' equity</b>							
Total current liabilities	885	1,163	1,299	1,231	1,284	1,275	1,334
Long-term loans	1,529	1,288	1,717	2,097	2,178	1,846	1,564
Total other non-current liabilities	274	319	501	529	508	491	526
Paid -up capital	900	977	1,016	1,016	1,016	1,016	1,016
Statutory reserves	155	1,121	1,742	1,742	1,742	1,742	1,742
Fair value adjustment	14	(2)	(2)	(2)	(2)	(2)	(2)
Retained earnings	921	1,108	1,368	1,595	1,902	2,286	2,691
Treasury shares	-	-	-	-	-	-	-
Non-controlling interest	242	269	305	342	380	419	458
Total owners' equity	2,232	3,473	4,428	4,693	5,038	5,461	5,904
<b>Total equity &amp; liabilities</b>	<b>4,920</b>	<b>6,243</b>	<b>7,945</b>	<b>8,551</b>	<b>9,008</b>	<b>9,073</b>	<b>9,328</b>
<b>Cashflow statement</b>							
Operating activities	442	626	600	649	899	1,067	1,215
Investing activities	(226)	(294)	(1,845)	(478)	(498)	(343)	(269)
Financing activities	(186)	(335)	1,081	(39)	(324)	(855)	(874)
Change in cash	30	(3)	(163)	132	78	(131)	72
<b>Ending cash balance</b>	<b>238</b>	<b>235</b>	<b>72</b>	<b>204</b>	<b>281</b>	<b>151</b>	<b>223</b>
<b>Key fundamental ratios</b>							
<b>Liquidity ratios</b>							
Current ratio (x)	1.3	1.5	1.2	1.0	1.4	1.5	1.4
Quick ratio (x)	1.2	1.0	0.8	1.1	1.2	1.2	1.3
<b>Profitability ratios</b>							
Gross profit margin	36.0%	36.7%	37.9%	34.1%	35.9%	37.0%	36.2%
Operating margin	15.8%	16.0%	17.4%	14.6%	17.6%	19.2%	19.0%
EBITDA margin	21.6%	21.5%	23.3%	20.6%	23.5%	24.9%	24.8%
Net profit margin	11.0%	12.2%	14.2%	10.8%	14.5%	16.6%	17.0%
Return on assets	5.7%	6.5%	6.5%	5.2%	7.3%	8.7%	9.9%
Return on equity	14.2%	13.9%	12.6%	10.2%	14.1%	16.3%	17.4%
<b>Leverage ratio</b>							
Debt / equity (x)	0.99	0.62	0.63	0.63	0.59	0.46	0.36
<b>Market/valuation ratios</b>							
EV/sales (x)	6.7	6.5	5.8	4.7	4.3	3.9	3.4
EV/EBITDA (x)	31.2	30.4	24.9	23.1	18.2	15.6	13.6
EPS (SAR)	2.7	3.7	4.6	4.2	6.3	7.8	9.0
BVPS (SAR) - Adjusted	22.11	32.79	40.59	42.83	45.86	49.64	53.62
Market price (SAR)*	148.00	171.80	160.80	160.80	160.80	160.80	160.80
Market-Cap (SAR mn)	15,032	17,450	16,332	16,332	16,332	16,332	16,332
Dividend yield	1.4%	1.2%	1.2%	1.2%	2.0%	2.5%	3.1%
P/E ratio (x)	54.8	46.4	35.3	37.9	25.6	20.7	17.9
P/BV ratio (x)	6.7	5.2	4.0	3.8	3.5	3.2	3.0

Sources: Aljazira Capital, Company Financials





RESEARCH DIVISION

Head of Sell-Side Research - AGM  
Jassim Al-Jubran  
+966 11 2256248  
j.aljabran@aljaziracapital.com.sa

RESEARCH  
DIVISION

AlJazira Capital, the investment arm of Bank AlJazira, is a Shariaa Compliant Saudi Closed Joint Stock company and operating under the regulatory supervision of the Capital Market Authority. AlJazira Capital is licensed to conduct securities business in all securities business as authorized by CMA, including dealing, managing, arranging, advisory, and custody. AlJazira Capital is the continuation of a long success story in the Saudi Tadawul market, having occupied the market leadership position for several years. With an objective to maintain its market leadership position, AlJazira Capital is expanding its brokerage capabilities to offer further value-added services, brokerage across MENA and International markets, as well as offering a full suite of securities business.

RATING  
TERMINOLOGY

1. **Overweight:** This rating implies that the stock is currently trading at a discount to its 12 months price target. Stocks rated "Overweight" will typically provide an upside potential of over 10% from the current price levels over next twelve months.
2. **Underweight:** This rating implies that the stock is currently trading at a premium to its 12 months price target. Stocks rated "Underweight" would typically decline by over 10% from the current price levels over next twelve months.
3. **Neutral:** The rating implies that the stock is trading in the proximate range of its 12 months price target. Stocks rated "Neutral" is expected to stagnate within +/- 10% range from the current price levels over next twelve months.
4. **Suspension of rating or rating on hold (SR/RH):** This basically implies suspension of a rating pending further analysis of a material change in the fundamentals of the company.

## Disclaimer

The purpose of producing this report is to present a general view on the company/economic sector/economic subject under research, and not to recommend a buy/sell/hold for any security or any other assets. Based on that, this report does not take into consideration the specific financial position of every investor and/or his/her risk appetite in relation to investing in the security or any other assets, and hence, may not be suitable for all clients depending on their financial position and their ability and willingness to undertake risks. It is advised that every potential investor seek professional advice from several sources concerning investment decision and should study the impact of such decisions on his/her financial/legal/tax position and other concerns before getting into such investments or liquidate them partially or fully. The market of stocks, bonds, macroeconomic or microeconomic variables are of a volatile nature and could witness sudden changes without any prior warning, therefore, the investor in securities or other assets might face some unexpected risks and fluctuations. All the information, views and expectations and fair values or target prices contained in this report have been compiled or arrived at by Al-Jazira Capital from sources believed to be reliable, but Al-Jazira Capital has not independently verified the contents obtained from these sources and such information may be condensed or incomplete. Accordingly, no representation or warranty, express or implied, is made as to, and no reliance should be placed on the fairness, accuracy, completeness or correctness of the information and opinions contained in this report. Al-Jazira Capital shall not be liable for any loss as that may arise from the use of this report or its contents or otherwise arising in connection therewith. The past performance of any investment is not an indicator of future performance. Any financial projections, fair value estimates or price targets and statements regarding future prospects contained in this document may not be realized. The value of the security or any other assets or the return from them might increase or decrease. Any change in currency rates may have a positive or negative impact on the value/return on the stock or securities mentioned in the report. The investor might get an amount less than the amount invested in some cases. Some stocks or securities maybe, by nature, of low volume/trades or may become like that unexpectedly in special circumstances and this might increase the risk on the investor. Some fees might be levied on some investments in securities. This report has been written by professional employees in Al-Jazira Capital, and they undertake that neither them, nor their wives or children hold positions directly in any listed shares or securities contained in this report during the time of publication of this report, however, The authors and/or their wives/children of this document may own securities in funds open to the public that invest in the securities mentioned in this document as part of a diversified portfolio over which they have no discretion. This report has been produced independently and separately by the Research Division at Al-Jazira Capital and no party (in-house or outside) who might have interest whether direct or indirect have seen the contents of this report before its publishing, except for those whom corporate positions allow them to do so, and/or third-party persons/institutions who signed a non-disclosure agreement with Al-Jazira Capital. Funds managed by Al-Jazira Capital and its subsidiaries for third parties may own the securities that are the subject of this document. Al-Jazira Capital or its subsidiaries may own securities in one or more of the aforementioned companies, and/or indirectly through funds managed by third parties. The Investment Banking division of Al-Jazira Capital maybe in the process of soliciting or executing fee earning mandates for companies that is either the subject of this document or is mentioned in this document. One or more of Al-Jazira Capital board members or executive managers could be also a board member or member of the executive management at the company or companies mentioned in this report, or their associated companies. No part of this report may be reproduced whether inside or outside the Kingdom of Saudi Arabia without the written permission of Al-Jazira Capital. Persons who receive this report should make themselves aware, of and adhere to, any such restrictions. By accepting this report, the recipient agrees to be bound by the foregoing limitations.

Asset Management | Brokerage | Investment Banking | Custody | Advisory

Head Office: King Fahad Road, P.O. Box: 20438, Riyadh 11455, Saudi Arabia, Tel: 011 2256000 - Fax: 011 2256068